Valuation: Capricor Therapeutics, Inc.

Market Cap 228M 197M 185M 168M 317M 21.71B 322M 2.17B 848M 10.87B 855M 836M 36.25B P/E 2026 *
-2.78x
P/E 2027 * -2.82x
Enterprise Value 228M 197M 185M 168M 317M 21.71B 322M 2.17B 848M 10.87B 855M 836M 36.25B EV / Sales 2026 *
3.51x
EV / Sales 2027 * 4.7x
Free-Float
90.53%
Yield 2026 *
-
Yield 2027 * -
1 day+2.08%
1 week-5.76%
Current month+2.08%
1 month-81.73%
3 months-87.68%
6 months-83.76%
Current year-86.38%
1 week 3.73
Extreme 3.73
4.7
1 month 2.96
Extreme 2.96
21.53
Current year 2.96
Extreme 2.96
36.82
1 year 2.96
Extreme 2.96
40.37
3 years 2.68
Extreme 2.68
40.37
5 years 2.56
Extreme 2.56
40.37
10 years 0.88
Extreme 0.88
42.5
Manager TitleAgeSince
Chief Executive Officer 62 20/11/2013
Director of Finance/CFO 40 01/01/2018
Chief Tech/Sci/R&D Officer - 13/05/2025
Director TitleAgeSince
Chairman 70 01/11/2013
Director/Board Member 68 20/11/2013
Director/Board Member 79 20/11/2013
Date Insider Type Main position Quantity % Market Cap.
2/4/26 Fiscal year

Director

22,587 0.0393%
5/1/26 Free

Director

15,500 0.0285%
5/1/26 Free

Chief Financial Officer

52,500 0.0965%
Change 5-day change 1-year change 3-year change Capi.($)
+2.08%-5.76%-49.71%-34.93% 223M
-0.70%+13.34%+75.61%+103.83% 70.85B
-2.35%+2.88%+35.39%+64.72% 55.41B
-1.62%+34.25%+17.43%+491.04% 29.43B
-1.35%+11.52%+53.25%+6.46% 24.12B
0.00%+1.59%-15.06%-13.21% 23.31B
+0.05%+6.12%+46.81%-21.81% 18.37B
+9.77%+20.16%+260.17%+472.38% 16.99B
-0.09%+6.85%+30.20%+619.86% 16.1B
-3.08%-8.34%+37.21%+138.52% 13.12B
Average +0.21%+353.07%+49.13%+182.69% 26.79B
Weighted average by Cap. -0.54%+350.47%+56.02%+166.67%

Financials

2026 *2027 *
Net sales 64.76M 56.12M 52.54M 47.94M 90.21M 6.18B 91.72M 616M 241M 3.09B 243M 238M 10.31B 48.38M 41.92M 39.25M 35.81M 67.39M 4.61B 68.52M 460M 180M 2.31B 182M 178M 7.7B
Net income -82.36M -71.38M -66.82M -60.97M -115M -7.86B -117M -784M -307M -3.93B -309M -303M -13.12B -83.73M -72.56M -67.93M -61.98M -117M -7.99B -119M -796M -312M -4B -314M -308M -13.34B
Net Debt - -
Logo Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program focuses on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, Deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. The clinical development program for Deramiocel has focused primarily on adolescents and young adults with DMD, including many patients who are non-ambulatory and experiencing progressive cardiac and skeletal muscle decline. Its StealthX exosome platform program consists of engineered exosomes for vaccine and therapeutic development. The StealthX vaccine is a proprietary vaccine developed internally utilizing exosomes that were engineered to express either spike or nucleocapsid proteins on the surface.
Employees
231
Date Price Change Volume
11/08/26 USD 3.930 +2.08% 3,325,986
10/08/26 USD 3.850 -5.87% 3,088,697
07/08/26 USD 4.090 -2.15% 3,618,170
06/08/26 USD 4.180 +6.36% 3,212,514
05/08/26 USD 3.930 -5.76% 3,678,169
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
3.930USD
Average target price
4.375USD
Spread / Average Target
+11.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CAPR Stock